UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of January 2026
Commission
File Number: 001-40678
EUDA
Health Holdings Limited
(Exact
Name of Registrant as Specified in its Charter)
60
Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: +65 6327 1110
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form
40-F ☐
Other
Events.
On
January 15, 2026, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.
Exhibits
| 99.1 |
|
Press
release dated January 15, 2026. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
| Dated:
January 15, 2026 |
|
| |
|
| EUDA
Health Holdings Limited |
|
| |
|
| By: |
/s/
Alfred Lim |
|
| |
Alfred
Lim |
|
| |
Chief
Executive Officer |
|
Exhibit 99.1
EUDA
Health Announces Second Amendment to Streeterville Warrant Agreement
SINGAPORE,
Jan. 15, 2026 (GLOBE NEWSWIRE) – EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”),
a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has entered
into a second amendment to its previously disclosed warrant agreement with Streeterville Capital, LLC.
Summary
of Second Warrant Amendment Terms
Under
the terms of the Second Warrant Amendment dated January 13, 2026, the Company and Streeterville Capital agreed to further reduce the
exercise price of the warrant from US$4.00 per share to US$2.00 per share. In addition, the minimum closing price of the Company’s
ordinary shares required to trigger a forced exercise under the warrant was reduced from US$6.00 to US$3.00. All other terms of the warrant
remain unchanged.
Mr
Alfred Lim, Chief Executive Officer of EUDA, commented:
“We
view this second amendment as a technical adjustment to align the warrant terms with current market conditions and to preserve flexibility
in our capital structure. It does not change our long-term strategy or operational priorities, and we remain focused on executing our
business plan across preventive health, longevity solutions, and personalised healthcare.”
About
EUDA Health Holdings Limited
EUDA
Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore,
Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the
fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which
is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and
science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment
to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking
Statements
This
document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words,
such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,”
“forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,”
“will,” “should,” “future,” “propose” and variations of these words or similar expressions
(or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions
or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are
outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking
statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document.
The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Christensen
Advisory
Christian
Arnell
Phone:
+ 852 9040 0621
Email:
christian.arnell@christensencomms.com
